Search This Blog

Monday, November 29, 2021

Krystal Biotech: Positive Topline Results in Dystrophic Epidermolysis Bullosa Trial



• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints,
and its secondary endpoint of complete wound healing at three-month timepoints

  • VYJUVEKTM was well tolerated, with no drug-related serious adverse events or discontinuations

  • Biologics License Application (BLA) on track to be submitted to U.S. Food and Drug Administration (FDA) in 1H22

  • Conference call to discuss results scheduled for today, Monday, November 29, 2021 at 8:00 a.m. EST


Investor Conference Call, Webcast and Presentation Information
Krystal will host an investor conference call and webcast today, Monday, November 29, at 8:00 a.m. ET, to discuss topline results from the pivotal GEM-3 trial and the VYJUVEKTM program. To participate in the conference call, please dial 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and refer to conference ID 13725260. The webcast, which will include presentation slides, will be available live and for replay on Krystal’s website at www.krystalbio.com in the Investors section.

https://finance.yahoo.com/news/krystal-biotech-announces-positive-topline-120000999.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.